Superworth

Ocular Therapeutix price to sales ratio OCUL

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026
27.4×
10-year median
43.0×
Against its 10-year history
39th
percentile: 0 is its lowest day, 100 its highest
10-year range
2.9× to 171×
Peer median
1.8×

Ocular Therapeutix's price to sales ratio is 27.4× as of Oct 23, 2026.

That is below its ten-year median of 43.0×, close to the middle of its last ten years.

Over that time it ranged from 2.9× in Nov 2023 to 171× in Jun 2017.

The median for 10 large drugmakers of a similar size is 1.8×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far27.4×27.4×46.7×
202548.0×15.9×55.6×
202421.6×5.3×28.9×
20236.1×2.9×11.1×
20224.4×4.0×12.8×
202113.8×12.2×128×
2020120×50.2×134×
201981.4×52.8×103×
201886.0×73.6×170×
201767.3×60.8×171×
2016115×60.7×176×
2015127×113×177×

Against its peers

Companies in Drug Manufacturers - General nearest Ocular Therapeutix's size, closest first, today.

CompanyPrice to sales ratio
OCULOcular Therapeutix27.4×
PCRXPacira BioSciences1.9×
ANABAnaptysbion/m
PAHCPhibro Animal Health1.0×
ANIPANI Pharmaceuticals1.7×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals1.5×
HRMYHarmony Biosciences2.2×
PBHPrestige Consumer Healthcare2.0×
ABUSArbutus Biopharma4.6×
COLLCollegium Pharmaceutical0.9×
Peer median1.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Ocular Therapeutix

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.